medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2009, Number 02

<< Back

Ginecol Obstet Mex 2009; 77 (02)

Clinical practice guidelines 2008. Mexican College of Obstetrics and Gynecology Specialists

Language: Spanish
References: 41
Page: 27-46
PDF size: 231.13 Kb.


ABSTRACT

No abstract


REFERENCES

  1. Summers AM, Farrell SA, Huang T, Meier C, Wyatt PR. Maternal serum screening in Ontario using the triple marker test. J Med Screen 2003;10:107-11.

  2. Driscoll DA. Second trimester maternal serum screening for fetal open neural tube defects and aneuploidy. ACMG Policy Statement Approved by the Board of Directors July 10, 2004. (http//www.acmg.net)

  3. Health Council of the Netherlands. Prenatal Screening (2); Down’s syndrome, neural tube defects. The Hague: Health Council of the Netherlands, 2004; publication No. 2004/06.

  4. SOGC Releases Guidelines on Prenatal Genetic Screening Ottawa Canada. The Society of Obstetricians www.sogc.org Feb 5, 2007.

  5. Cuckle HS, Wald N. Test using single markers. In: Wald N, Lek I, eds. Antenatal and Neonatal Screening. Oxford University Press, 2000;pp:3-19.

  6. Wald NJ, Leck I. Antenatal and neonatal screening. 2nd ed 2000; p:88.

  7. Mutchinick O, Lisker R, Babinsky V. Riesgo para síndrome de Down por bienios y quinquenios de edad materna en la población mexicana. Bol Med Hosp Infant Mex 1991;48:534-7.

  8. Wald NJ, Leck I. Antenatal and neonatal screening. 2nd ed 2000;p:89.

  9. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnarmalities. Am J Obstet Gynecol 2004;191:45-67.

  10. Cleary-Goldman J, Morgan MA, Malone FD, Robinson JN, et al. Screening for Down syndrome: practice patterns and knowledge of obstetricians and gynecologists. Obstet Gynecol 2006;107:11-7.

  11. Acuña J, Yoom P, Erickson JO. La prevención de los defectos del tubo neural con ácido fólico. CDC Organización Pana mericana de la Salud. www.cdc.gob

  12. Alldred SK, Alfirevic Z, Oeeks JJ, Neilson JP. Antenatal screening for detecting Down’s syndrome [monograph on the Internet). Chichester: Wiley, 2007. Available from: http//www.interscience.wiley.com/cgibin/mrwhome/106568753/ DTAP1.

  13. Prenatal screening tests for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) and neural tube defects. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. ABN 34 100 www.nuchaltrans.edu. au/268 969 Julio 2007.

  14. Livesey EA, Noon M. Implementing guidelines: what works? Arch Ois Child Educ Pract Ed 2007; 92:ep129-ep134. doi: 10.1136/adc.2005.093328

  15. Kirkham C, Harris S, Grzybowski S. University 01 British Columbia, Vancouver, British Columbia, Canada: Evidence-Based Prenatal Care: Part 1. General Prenatal Care and Counseling Issues American Family Physician, April1, 2005(71);7. www. aalp.arg/alp

  16. Resta RG. Changing demographics 01 advances maternal age (AMA) and the impact on the predicted incidence 01 Down syndrome in the United States: Implications lor prenatal screening and genetic counseling. Am J Med Genet A 2005;133:31-6.

  17. Wenstrom K. Evaluation 01 Oown Syndrome Screening Strategies. Semin Perinatol 2005;29:219-24.

  18. Nicolaides KH, Snijders RJ, Gosden CM, Berry C, Campbell S. Ultrasonographically detectable markers 01 letal chromo somal abnormalities. Lancet 1992:340:704-7.

  19. Nicolaides KH, Heath V, Liao AW. The 11-14 week sean. Bailleres Best Pract Res Clin Obstet Gynaecol 2000;14:581-94.

  20. Snijders RJ, Tom EA, Zachary JM, Platt LO, Greene N, Jacson LG, et al. First-trimester trisomy screening: nuchal translucen cy measurement training and quality assurance to carrect and unily technique. Ultrasound Obstet GynecoI2002;19:353-9.

  21. Nicolaides KH, Azar G, Birne O, Mansur C, Marks K: Fetal nuchal translucency: ultrasound screening lar chromosomal delects in lirst trimester 01 pregnancy. BMJ 1992;304:867-9.

  22. Orlando F, Oamian G, Hallahan TW, Krantz DA, Macri JN: First trimester screening lor letal aneuploidy’ biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 1997;10:381-6.

  23. Wald NJ, Hackshaw AK.Combining ultrasound and biochemistry in lirst trimester screening lar Oown’s syndrome. Prenat Diagn 1997; 17:821-9.

  24. Glenn E. Palomaki, BS1, Linda A Bradley, Ph02, and Geraldine A McDowell. Down Syndrome Working Group. ACMG Laboratory Quality Assurance Committee ACMG Standards and Guidelines. Technical standards and guidelines: Prenatal screening for Down syndrome. Genetics in Medicine 2005(7);5.

  25. ACMG Practice Guidelines. Oriscoll DA, Gross SJ. First trimester diagnosis and screening lor letal aneuploidy. 2008; 10(1): 73-5.

  26. Lee CP, Tang M, Tang R, Tse HY, et al. Acceptability of first and second trimester screening for fetal Down´s syndrome-interim results from a demonstration trial. International Society for Prenatal Diagnosis. 12th International Conference on Prenatal Diagnosis and Therapy, Budapest, 2004; Abstract 71.

  27. Wald NJ, Leck I. Antenatal and neonatal screening. 2nd. ed.; 2000. p. 68-72.

  28. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First and Second Trimester evaluation of risk (FASTER) Research Consortium. First-trimester or second trimester screening, or both, for Down’s syndrome. N Engl J Med 2005;353:2001-11 .

  29. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down’s syndrome. J Med Screen 1997;4:181-246.

  30. Wald NJ, Leck I. Antenatal and neonatal screening. 2nd. ed.; 2000. p. 68-72.

  31. Wald NJ, Leck I. Antenatal and neonatal screening. 2nd. ed.; 2000. p. 68-69.

  32. Caughey AB, Hopkins LM, Norton ME. Charionic villus sampling compared with amniocentesis and the differenc rate 01 pregnancy loss. Obstet GynecoI2006;108612-6.

  33. Scott F, Peters H, Boogert 1, Robertson R, et al. The loss rates for invasive prenatal testing in a specialized obstetr sound practice. Aust NZJ Obstet Gynecol 2002;42:55-8.

  34. Alfi revic Z, Sundberg K, Brigham S. Amniocentesis and charionic villus sampling for prenatal diagnosis. Cochran base Syst Rev. 2003; (3):C0003252.

  35. Committee on Practice Bulletins. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnorr Obstet GynecoI2007;109:217-27.

  36. Cuckle HS, Wald N. Test using single markers. In: Wald N, Lek 1, eds. Antenatal and Neonatal screening. Oxford Ur Press; 2000. p. 3-19.

  37. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al: First trimester screening far trisomies 21 N Engl J Med 2003;349:1405-13.

  38. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM: First and second trimester antenatal ning far Oown’s syndrome: the results of the Serum, Urine, and Ultrasound Screening Study (SURUSS). J Med 2003; 1 0:56-1 04.

  39. Wald NJ, Kennard A, Hackshaw A, McGuire A: Antenatal screening far Oown’s syndrome. J Med Screen 1977;4:18

  40. Summers AM, Farell SA, Huang 1, Meier C, Wyatt PR: Maternal serum screening in Ontario using the triple marke Med Screen 2003;10:107-11.

  41. Summers AM, Langlois S, Wyatt P, Wilson RO: SOGC Clinical Practice Guidelines. Prenatal Screening far fetal anel JOGC 2007;187:146-61.




2020     |     www.medigraphic.com